Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing. For more information, please visit http://www.xcellbio.com/.
Location: United States, California, San Francisco
Employees: 11-50
Phone: +1 415-937-0321
Total raised: $39.5M
Founded date: 2012
Investors 2
| Date | Name | Website |
| 10.03.2024 | RONA Holdi... | ronaholdin... |
| - | Avego | avego.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.01.2022 | Series B | $27.5M | - |
| 22.02.2017 | Series A | $12M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 19.01.2022 | Xcellbio Closes $27.5M Series B Financing | SAN FRANCISCO, CA, Xcell Biosciences, a developer of cell and gene therapies, announced $27.5 mill... | vcnewsdail... |
| 19.01.2022 | Dynamk Capital Joins World-Class Syndicate of LS Investors P... | Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms d... | dynamk.vc/... |
| 19.01.2022 | Xcellbio Announces $27.5 Million Series B Financing | Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms d... | marketscre... |
| 04.01.2018 | Xcell Biosciences Announces New Emphasis Towards Immunothera... | Company Welcomes Janette Phi as Chief Operations Officer SAN FRANCISCO–(BUSINESS WIRE)–January 4, 20... | venturebea... |
| 16.02.2017 | Term Sheet — Thursday, February 16 | SNAP CRACKLE DROP Snap goes low: Either Snap is setting itself up for a big pop, or the company’s un... | fortune.co... |
| 16.02.2017 | Xcell Biosciences Receives $12M Series A Funding Round | Xcell Biosciences, a San Francisco, CA-based provider of an advanced primary cell culturing platform... | finsmes.co... |
| 16.02.2017 | Xcell Biosciences Announces $12 Million Series A Funding Rou... | Investors include HBM Genomics and Viking Global Investors Company to expand commercial efforts for ... | venturebea... |